PRECISION BIOSCIENCES INC

DTIL

PRECISION BIOSCIENCES INC

DTIL

Insider Sentiment (TTM):

Last Purchase:2025-12-16Last Sale:2026-02-18Shares Purchased (TTM):11,181Shares Sold (TTM):113,001

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:15,971,951Shares Outstanding:24,634,443Institutional Ownership Pct.:64.84%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	86	99	111	45	62	77	86	99	124	138	117	122
Accounts Receivable Net Current	0	4	0	0	0	0	0	0	0	0	1	4
Marketable Securities Current	1	2	5	0	0	-	0	2	-	-	-	-
Prepaid Expense Current	4	4	3	6	7	5	6	7	6	9	6	8
Notes And Loans Receivable Net Current	-	-	-	-	-	-	-	-	12	12	12	12
Assets Held For Sale Not Part Of Disposal Group Cu…	-	-	0	0	0	0	0	0	0	0	0	-
Other Assets Current	0	0	0	1	0	0	0	0	1	0	0	0
Assets Current	92	109	119	52	70	82	95	111	144	161	136	146
Restricted Cash And Cash Equivalents	26	26	26	26	23	23	23	23	-	-	-	-
Property Plant And Equipment Net	1	1	1	2	2	3	3	4	4	5	6	9
Intangible Assets Net Excluding Goodwill	1	1	1	1	1	1	1	0	0	0	0	1
Operating Lease Right Of Use Asset	5	5	6	6	6	7	7	7	8	8	8	1
Equity Securities F V N I Noncurrent	1	1	1	1	1	3	3	3	3	3	3	2
Notes Receivable Net	-	-	0	5	6	6	5	5	6	7	5	6
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	126	144	154	94	109	124	136	153	166	185	160	164
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	0	1	1	1	1	1	1	1	3	1
Employee Related Liabilities Current	2	1	5	3	2	1	5	4	2	1	5	4
Contract With Customer Liability Current	-	-	0	6	6	6	3	0	1	2	12	17
Loans Payable Current	-	-	-	-	-	-	-	-	22	22	22	22
Operating Lease Liability Current	2	2	2	1	1	1	1	1	1	1	1	1
Other Liabilities Current	1	1	1	1	1	1	1	1	2	3	2	2
Liabilities Of Disposal Group Including Discontinu…	-	-	0	1	1	1	1	1	1	2	3	2
Liabilities Current	7	8	9	15	14	12	15	12	33	33	50	51
Loans Payable	22	22	22	22	22	22	22	22	-	-	-	-
Contract With Customer Liability Noncurrent	-	-	0	20	20	21	23	27	27	75	73	74
Operating Lease Liability Noncurrent	4	4	5	5	6	6	6	7	7	7	8	-
Business Combination Contingent Consideration Liab…	10	10	10	10	10	10	10	10	10	10	10	10
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	-	-	0	1
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	-	-	-	-	0	-
Liabilities	81	68	62	77	75	75	80	88	91	148	141	135
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	-	0	-	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	626	624	621	566	562	553	540	531	524	519	509	503
Retained Earnings Accumulated Deficit	-579	-547	-528	-548	-527	-503	-482	-465	-448	-481	-490	-473
Treasury Stock Value	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1
Stockholders Equity	45	76	92	17	34	49	56	65	75	37	19	29
Liabilities And Stockholders Equity	126	144	154	94	109	124	136	153	166	185	160	164
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	26	26	24	12	12	11	8	8	7	7	4	4
Shares Outstanding	26	26	24	12	12	11	8	7	7	7	4	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.44%	-2.15%	-2.15%	-	-	-	-	-	-	-	-	-
2025	20.66%	-4.62%	1.54%	7.22%	10.72%	47.05%	-26.09%	-42.53%	-42.93%	2.65%	28.40%	22.93%
2024	6.09%	-20.00%	-18.96%	1.25%	0.42%	-6.58%	-12.06%	-43.91%	-38.72%	10.82%	3.97%	8.17%
2023	-	-	-	-	-	-	-6.41%	-6.41%	-7.18%	-24.96%	-4.47%	-14.33%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	12.82	14.02	13.32	3.45	5.18	6.62	6.34	9.22	4.37	4.82	2.73	2.88
Quick Ratio	12.26	13.56	12.97	3.06	4.63	6.25	5.91	8.63	4.20	4.55	2.61	2.72
Working Capital	84.41M	100.94M	109.83M	36.71M	56.69M	69.71M	80.01M	98.54M	111.08M	127.49M	86.37M	95.24M
Leverage & Debt
Debt to Equity	1.78	0.89	0.67	4.62	2.20	1.52	1.42	1.36	1.22	3.97	7.47	4.65
Interest Coverage TTM	-10.49	-11.09	-14.61	-61.05	-66.26	-28.22	-14.68	-8.23	-3.19	-15.15	-19.61	-9.17
Debt Ratio	0.64	0.47	0.40	0.82	0.69	0.60	0.59	0.58	0.55	0.80	0.88	0.82
Efficiency & Turnover
Asset Turnover TTM	0.38	0.34	0.24	0.01	0.01	0.33	0.46	0.47	0.50	0.30	0.24	0.24
Days Sales Outstanding TTM	-	16.21	-	50.20	-	1.41	3.00	8.99	1.79	3.44	6.07	14.75
Receivables Turnover TTM	-	22.51	-	7.27	-	259.60	121.59	40.61	204.05	106.15	60.12	24.75
Per Share Metrics
Diluted EPS TTM	-2.04	-1.77	-3.56	-7.07	-7.08	-2.37	1.04	1.18	2.42	-5.46	-15.96	-19.15
Free Cash Flow Per Share TTM	-2.29	-2.39	-5.15	-4.61	-4.09	-6.32	-8.59	-6.64	-9.46	-14.46	-22.42	-26.09
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	103.05%	102.59%	102.62%	102.61%	103.97%	104.58%	104.09%
Operating Profit Margin TTM	-80.78%	-86.77%	-152.19%	-12,822.64%	-7,145.92%	-86.21%	-38.08%	-21.58%	-8.32%	-60.09%	-89.76%	-37.46%
Net Profit Margin TTM	-117.04%	-96.73%	-133.45%	-11,977.36%	-6,205.79%	-42.99%	10.43%	11.48%	19.36%	-48.10%	-125.84%	-140.60%
Growth Metrics
Net Revenue Growth (1Y)	3,472.96%	-11.87%	-50.12%	-99.07%	-98.56%	-11.11%	40.98%	43.62%	88.35%	88.25%	94.15%	150.91%
Net Income Growth (1Y)	-32.62%	98.31%	-737.98%	-1,069.52%	-561.16%	-20.54%	-111.69%	-111.73%	-118.98%	-74.50%	-45.07%	-30.27%
EPS Growth (1Y)	-71.21%	-25.20%	-439.88%	-697.82%	-390.84%	-56.72%	-106.57%	-106.18%	-110.36%	-81.31%	-58.11%	-32.96%
Valuation Metrics
P/E TTM	-3.85	-3.11	-1.17	-0.78	-0.59	-2.02	3.63	7.57	3.99	-2.48	-0.69	-0.53
P/B TTM	4.49	1.78	0.58	3.92	1.36	0.90	0.46	1.01	0.91	1.84	2.23	1.35
P/S TTM	4.51	3.01	1.56	93.46	36.79	0.87	0.38	0.87	0.77	1.19	0.86	0.75
Market Cap	203.23M	135.49M	53.36M	65.24M	46.39M	44.32M	26.03M	65.29M	67.79M	68.63M	42.06M	39.27M
Enterprise Value	90.83M	9.64M	-83.80M	-5.98M	-38.41M	-55.47M	-82.43M	-56.03M	-33.29M	-46.68M	-52.20M	-60.59M
Calculated Values
Free Cash Flow TTM	-59.13M	-58.89M	-66.05M	-54.45M	-45.13M	-58.74M	-58.70M	-48.36M	-65.89M	-73.21M	-86.12M	-100.15M
Net Debt	-112.41M	-125.85M	-137.15M	-71.21M	-84.81M	-99.79M	-108.47M	-121.33M	-101.08M	-115.31M	-94.27M	-99.87M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-18Sale

Owner: Kelly, John Alexander

Title: Chief Financial Officer

Shares: 8,149

Price/Share: $3.84

Value: $31,292.16

Shares Owned: 125,883

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Scimeca, Dario

Title: General Counsel and Secretary

Shares: 4,925

Price/Share: $3.84

Value: $18,912.00

Shares Owned: 56,457

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Smith, J. Jefferson

Title: Chief Research Officer

Shares: 4,925

Price/Share: $3.84

Value: $18,912.00

Shares Owned: 121,926

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Amoroso, Michael

Title: President and CEO

Shares: 20,559

Price/Share: $3.84

Value: $78,946.56

Shares Owned: 243,392

Relationship: Director,Officer

Ownership: Direct

2026-01-22Sale

Owner: Amoroso, Michael

Title: President and CEO

Shares: 34,799

Price/Share: $4.17

Value: $145,111.83

Shares Owned: 196,154

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-18	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Sale	8,149	3.84	$31,292.16	125,883	4
2026-02-18	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	4,925	3.84	$18,912.00	56,457	4
2026-02-18	Smith, J. Jefferson	Officer	Chief Research Officer	Direct	Sale	4,925	3.84	$18,912.00	121,926	4
2026-02-18	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	20,559	3.84	$78,946.56	243,392	4
2026-01-22	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	34,799	4.17	$145,111.83	196,154	4
2026-01-21	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	8,854	4.03	$35,681.62	44,715	4
2026-01-21	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Sale	15,213	4.03	$61,308.39	106,448	4
2026-01-21	Smith, J. Jefferson	Officer	Chief Research Officer	Direct	Sale	10,200	4.03	$41,106.00	110,184	4
2025-12-16	Germano, Geno J	Director	-	Direct	Purchase	3,000	4.72	$14,160.00	23,883	4
2025-12-16	Frankel, Stanley	Director	-	Direct	Purchase	2,700	4.70	$12,690.00	19,478	4
2025-12-15	Brown, Melinda	Director	-	Direct	Purchase	1,381	4.97	$6,863.57	23,346	4
2025-11-03	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	665	6.49	$4,315.85	28,258	4
2025-11-03	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Sale	1,303	6.49	$8,456.47	77,298	4
2025-11-03	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	3,409	6.49	$22,124.41	115,575	4
2025-09-26	Frankel, Stanley	Director	-	Direct	Purchase	2,700	4.97	$13,419.00	16,778	4
2025-09-22	Brown, Melinda	Director	-	Direct	Purchase	1,400	4.89	$6,846.00	21,965	4
2025-07-03	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Sale	14,827	4.26	$63,163.02	73,485	4
2025-06-25	Buehler, Kevin	Director	-	Direct	Purchase	5,076	4.16	$21,116.16	28,137	4
2025-06-25	Brown, Melinda	Director	-	Direct	Purchase	1,682	4.14	$6,963.48	20,565	4
2025-03-26	Buehler, Kevin	Director	-	Direct	Purchase	4,523	4.67	$21,122.41	13,235	4
2025-03-26	Brown, Melinda	Director	-	Direct	Purchase	1,839	4.75	$8,735.25	9,057	4
2025-03-25	Germano, Geno J	Director	-	Direct	Purchase	3,250	5.30	$17,225.00	11,057	4
2025-03-24	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	964	5.56	$5,359.84	109,540	4
2025-03-04	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	272	4.91	$1,335.52	25,000	4
2025-03-04	Smith, J. Jefferson	Officer	Chief Research Officer	Direct	Sale	154	4.91	$756.14	87,805	4
2025-01-22	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	8,928	4.79	$42,765.12	24,353	4
2025-01-22	Smith, J. Jefferson	Officer	Chief Research Officer	Direct	Sale	10,287	4.79	$49,274.73	87,440	4
2025-01-21	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	36,838	4.67	$172,033.46	107,087	4
2024-12-30	Germano, Geno J	Director	-	Direct	Purchase	3,605	4.49	$16,186.45	7,807	4
2024-12-27	Buehler, Kevin	Director	-	Direct	Purchase	4,320	4.88	$21,081.60	8,712	4
2024-12-27	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Purchase	2,113	4.75	$10,036.75	40,186	4
2024-12-26	Brown, Melinda	Director	-	Direct	Purchase	3,016	4.55	$13,722.80	7,218	4
2024-11-21	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Purchase	3,000	6.76	$20,280.00	38,073	4
2024-11-04	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	588	8.19	$4,815.72	7,969	4
2024-11-04	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	3,012	8.19	$24,668.28	28,537	4
2024-06-10	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	93	11.79	$1,096.47	6,721	4
2024-06-10	Smith, J. Jefferson	Officer	Chief Research Officer	Direct	Sale	50	11.79	$589.50	68,559	4
2024-05-02	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	1,526	10.32	$15,748.32	13,772	4
2024-05-02	List, Alan	Officer	Chief Medical Officer	Direct	Sale	290	10.32	$2,992.80	4,488	4
2024-05-02	Smith, J. Jefferson	Officer	Chief Research Officer	Direct	Sale	154	10.32	$1,589.28	67,613	4
2024-05-02	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	272	10.32	$2,807.04	5,680	4
2024-04-30	List, Alan	Officer	Chief Medical Officer	Direct	Sale	238	10.03	$2,387.14	3,796	4
2024-01-23	Smith, J. Jefferson	Officer	Chief Research Officer	Direct	Sale	28,000	0.37	$10,360.00	1,987,269	4
2024-01-22	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	137,390	0.36	$49,460.40	356,433	4
2024-01-22	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	21,287	0.36	$7,663.32	151,028	4
2024-01-22	List, Alan	Officer	Chief Medical Officer	Direct	Sale	21,526	0.36	$7,749.36	94,982	4
2023-11-03	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	125,025	0.40	$50,010.00	227,103	4
2023-11-03	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	16,023	0.40	$6,409.20	112,970	4
2023-08-18	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Purchase	90,000	0.48	$43,200.00	383,340	4/A
2023-06-08	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	13,361	0.75	$10,020.75	68,473	4
2023-04-27	List, Alan	Officer	Chief Medical Officer	Direct	Sale	7,771	0.79	$6,139.09	56,496	4
2023-03-22	Amoroso, Michael	Director,Officer	President and CEO	Direct	Sale	46,999	0.82	$38,539.18	68,738	4
2023-03-17	Kelly, John Alexander	Officer	Chief Financial Officer	Direct	Purchase	20,000	0.86	$17,200.00	245,614	4
2023-03-06	List, Alan	Officer	Chief Medical Officer	Direct	Sale	9,473	1.07	$10,136.11	38,240	4
2023-03-06	Scimeca, Dario	Officer	General Counsel and Secretary	Direct	Sale	12,172	1.07	$13,024.04	50,063	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

64.84%

Inst. Shares: 15,971,951

Shares Outstanding: 24,634,443

2025-12-31

116.95%

Inst. Shares: 15,000,216

Shares Outstanding: 12,826,078

2025-09-30

37.53%

Inst. Shares: 4,435,702

Shares Outstanding: 11,818,145

2025-06-30

37.64%

Inst. Shares: 4,158,338

Shares Outstanding: 11,046,401

2025-03-31

37.66%

Inst. Shares: 3,499,476

Shares Outstanding: 9,292,066

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	15,971,951	24,634,443	64.84%
2025-12-31	15,000,216	12,826,078	116.95%
2025-09-30	4,435,702	11,818,145	37.53%
2025-06-30	4,158,338	11,046,401	37.64%
2025-03-31	3,499,476	9,292,066	37.66%
2024-12-31	3,594,427	6,832,982	52.60%
2024-09-30	3,170,614	7,287,173	43.51%
2024-06-30	3,032,416	6,966,680	43.53%
2024-03-31	2,937,659	5,060,978	58.05%
2023-12-31	28,894,767	3,841,405	-
2023-09-30	29,513,321	3,838,900	-
2023-06-30	38,080,800	3,803,083	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

PRECISION BIOSCIENCES INC (DTIL) — SEC Financial Statements & Analysis

PRECISION BIOSCIENCES INC (DTIL) is a biological products, (no diagnostic substances) company, incorporated in DE. PRECISION BIOSCIENCES INC trades on Nasdaq as: DTIL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), PRECISION BIOSCIENCES INC reported a 3472.96% year-over-year revenue growth, a Gross Profit Margin of 103.05% (TTM), a Debt-to-Equity ratio of 1.78x, a Price-to-Sales (P/S) ratio of 4.51x (TTM), a Price-to-Book (P/B) ratio of 4.49x (TTM), at a market cap of $203.23M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 3472.96%
Gross Profit Margin TTM: 103.05%
Debt To Equity: 1.78x
P/S TTM: 4.51x
P/B TTM: 4.49x
Market Cap: $203.23M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is PRECISION BIOSCIENCES INC in?

PRECISION BIOSCIENCES INC (DTIL) operates in the Biological Products, (No Diagnostic Substances) industry.

What is DTIL's market cap?

PRECISION BIOSCIENCES INC (DTIL) has a market capitalization of $203.23M as of 2026-06-30.

What exchange does DTIL trade on?

PRECISION BIOSCIENCES INC (DTIL) trades on the Nasdaq.

Where is PRECISION BIOSCIENCES INC incorporated?

PRECISION BIOSCIENCES INC is incorporated in DE.